Decapeptide-12
Lumixyl
COSMETIC CLINICAL STUDIES · COSMETIC PEPTIDE; TYROSINASE INHIBITOR
▓ 9 indexed citations across PubMed (7), EuropePMC (2).
Citation breakdown by evidence tier
← weaker evidence · stronger evidence →
Tap any tier to jump to that section of the bibliography.
Mechanism of action
Competitive tyrosinase inhibition; reduces melanin synthesis
Researched effects
Skin brightening; melasma reduction; hyperpigmentation
Live evidence
Recent literature
- Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review.
- Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles.
- Enhanced skin permeation of a novel peptide via structural modification, chemical enhancement, and microneedles
Live signals refreshed daily. Current as of November 19, 2026.
Dosing reported in literature
Topical 0.01-0.1%
Known concerns
Minimal; slow visible results
Top-ranked picks
7 pre-curated authoritative sources, ranked by journal tier and study weight.
- A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma.
- Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma.
- Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12.
- Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review.
- Enhanced skin retention and permeation of a novel peptide via structural modification, chemical enhancement, and microneedles.
- Efficacy of Trifecting
- Combined topical delivery and dermalinfusion of decapeptide-12 accelerates resolution of post-inflammatory hyperpigmentation in skin of color.
Full citation library
Year distribution
No references match — clear filters.
Randomised Controlled Trials
1-
1.
Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl) was previously shown to competitively inhibit mushroom and human tyrosinase without the associated toxicity of hydroquinone. The aim of this split-face, randomized, double-blind and placebo-controlled pilot study was to determine the effect of twice-daily topical application of this oligopeptide (0.01% w/w) on moderate, recalcitrant melasma over a 16-week co…
Clinical Trials
2-
2.
This prospective study evaluated the safety and efficacy of decapeptide-12 in conjunction with an antioxidant cleanser, glycolic-acid containing facial moisturizer and broad-spectrum sunscreen in the treatment of facial hyperpigmentation associated with chronic photodamage. Fifteen female subjects with Fitzpatrick skin types I through IV and documented photodamage were entered into the study, of whom 13 completed the study. Results were obtained at weeks 4, 8, 12, 18 and 24 and were assessed by…
-
3.
Melasma is a cutaneous disorder that primarily affects females of Hispanic and Asian descent. Previous studies have shown that use of a brightening system comprised of 0.01% decapeptide-12 cream, an antioxidant cleanser, a 20% buffered glycolic acid lotion, and a broad spectrum SPF 30 sunscreen yields good clearance of mild-to-moderate melasma in Caucasian and Asian volunteers. The present open-label, prospective, and multicenter study sought to determine the tolerability and efficacy of the abo…
Research Articles
4- 4.
-
5.
Hyperpigmentation is a common skin condition with serious psychosocial consequences. Decapeptide-12, a novel peptide, has been found to be safer than hydroquinone in reducing melanin content, with efficacy up to more than 50% upon 16 weeks of twice-daily treatment. However, the peptide suffers from limited transcutaneous penetration due to its hydrophilicity and high molecular weight. Therefore, decapeptide-12 was modified by adding a palmitate chain in an attempt to overcome this limitation. Mo…
- 6.
-
7.
One class of cosmetic compounds that have raised interest of many experts is peptides. The search for ingredients with good biocompatibility and bioactivity has led to the use of peptides in cosmetic products. Peptides are novel active ingredients that improve collagen synthesis, enhance skin cell proliferation, or decrease inflammation. Based on their mechanism of action, they can be classified into signal peptides, carrier peptides, neurotransmitter inhibitor peptides, and enzyme inhibitor pep…
Preprints (not yet peer-reviewed)
1-
8.
Hyperpigmentation is a common skin condition with serious psychosocial consequences. Decapeptide-12, a novel peptide, has been found to be safer than hydroquinone in reducing content of melanin, with efficacy up to more than 50% upon 16 weeks of twice daily treatment. However, the peptide suffers from limited transcutaneous penetration due to its hydrophilicity and large molecular weight. Therefore, decapeptide-12 was modified by adding a palmitate chain in an attempt to overcome this limitation…
Case Reports
1-
9.
Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl™) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma. The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oligopeptide cream, an antioxidant cleanser, 20% glycolic acid lotion and physi…
Curated sources on file
3- 1.
- 2.
-
3.
Note: Primary literature for this commercial cosmetic peptide is limited; cited reviews summarize available preclinical and clinical evidence.